Company Profile

Yaupon Therapeutics Inc
Profile last edited on: 2/19/19      CAGE: 47C01      UEI:

Business Identifier: Small molecule drug development: Rare cancers
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

101 Lindenwood Drive Suite 400
Malvern, PA 19355
   (610) 975-9290
Location: Single
Congr. District: 06
County: Chester

Public Profile

Doing business for over a decade as Yaupon Therapeutics, Inc, primarily organized around IP licensed from the University of Kentucky, the firm has been working on utilizing transdermal delivery technology to deliver S-(-)-nornicotine through skin for the treatment of nicotine dependence. Plants had for centuries been known a repository of naturally occurring compounds to treat disease. Yaupon was applying modern techniques to identify valuable medicines that address unmet medical needs. In January 2012, the firm changed its name to Ceptaris Therapeutics Inc. and shifted focus to development of mechlorethamine gels using a formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. By September 2013, Ceptaris Therapeutics Inc. was acquired and operates as a subsidiary of Actelion US Holding Company.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2008 2 NIH $326,551
Project Title: Lobeline Clinical Study in ADHD
2008 2 NIH $1,193,974
Project Title: Norketamine for Treatment of Pain
2007 1 NIH $172,935
Project Title: Nornicotine for Treatment of Pain
2006 2 NIH $1,014,898
Project Title: Nornicotine Enantiomers and Nicotine Self Administration

Key People / Management

  Steve Tullman -- Chairman & CEO

  Tim Henckel

Company News

There are no news available.